Generally, we observed that the levels of Y228-phosphorylated p120 were higher in tumor samples from patients with astrocytomas or GBMs than those from patients with breast or prostate cancer (Figure 1C). This evidence concerns the gene CTNND1 and astrocytoma (excluding glioblastoma).